En del af firmaets bestyrelse / direktion har benyttet det smalle vindue til at omsætte lidt af deres aktio optionsløn til cash - men de har lige fået flere optioner - så ejerskabet er stort set ens - undtaget "ham" der skal på pension,
og firmaet har solgt noget af de aktier der var aftalt skulle sælges ved sidste generalforsamling
så de har fået cash at arbejde videre med
og der er nu opslået 61 stillinger - som tyder på at produktionen er på trapperne
endelig så har FDA:
Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track review status to PROVENGE� (sipuleucel-T) for its proposed use in the treatment of asymptomatic men with metastatic, androgen-independent prostate cancer.
der er fortsat mange short i aktien
og der er optionsudløb den 9 maj - hvor der fortsat er mange der ligger skævt
derudover er der margincall's på vej
alt i alt synes jeg det ser OK ud og fastholder min position.
Hya
og firmaet har solgt noget af de aktier der var aftalt skulle sælges ved sidste generalforsamling
så de har fået cash at arbejde videre med
og der er nu opslået 61 stillinger - som tyder på at produktionen er på trapperne
endelig så har FDA:
Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track review status to PROVENGE� (sipuleucel-T) for its proposed use in the treatment of asymptomatic men with metastatic, androgen-independent prostate cancer.
der er fortsat mange short i aktien
og der er optionsudløb den 9 maj - hvor der fortsat er mange der ligger skævt
derudover er der margincall's på vej
alt i alt synes jeg det ser OK ud og fastholder min position.
Hya
5/5 2009 21:32 Hya 0
10061 sorry for sproglige og tastemæssige fejl - er ik lige min mest aktive dag!
Hya
Hya
6/5 2009 13:51 Hya 010155 http://www.xconomy.com/seattle/2009/05/0...
Dendreon Goes on Hiring Binge After Prostate Cancer Drug Boosts Survival
Luke Timmerman 5/6/09
Dendreon partied at a medical meeting last week in Chicago after it showed that its immune-stimulating therapy could extend the lives of prostate cancer patients with minimal side effects. Now the biotech company is fast at work again, looking to hire 60 new people to make sure it performs all the work necessary to turn its drug into a blockbuster.
The Seattle-based company (NASDAQ: DNDN) has posted almost all of these new positions on its website in the past week. It is looking to fill 37 spots at headquarters, another 32 at its commercial manufacturing plant in Morris Plains, NJ, and one person in Research Triangle Park, NC, where it has an important relationship with a supplier. Dendreon had just 198 total employees at last count on March 2, so this represents a 30 percent expansion.
The job descriptions posted online represent a broad range of skills Dendreon will need to maximize the value of sipuleucel-T (Provenge). Dendreon is looking for people in quality assurance and quality control, finance, marketing, human resources, and logistics. These people, together with the current Dendreon staff, will be charged with amending an application to the FDA to start marketing the drug in the U.S., and then producing enough of the drug to meet demand. Prostate cancer kills 30,000 men nationwide each year, and analysts predict the product—the first drug of its kind likely to win FDA approval—will go on to exceed $1 billion a year in sales.
Dendreon has been mum about the commercial game plan it needs to execute to make this really happen, deferring all questions about strategy to an analyst day it plans to host this summer. But it confirmed the massive push is on to hire and grow.
“Dendreon is beginning hiring to support the regulatory and commercial plans for Provenge,” said Katherine Stueland, a spokeswoman for the company....
Dendreon Goes on Hiring Binge After Prostate Cancer Drug Boosts Survival
Luke Timmerman 5/6/09
Dendreon partied at a medical meeting last week in Chicago after it showed that its immune-stimulating therapy could extend the lives of prostate cancer patients with minimal side effects. Now the biotech company is fast at work again, looking to hire 60 new people to make sure it performs all the work necessary to turn its drug into a blockbuster.
The Seattle-based company (NASDAQ: DNDN) has posted almost all of these new positions on its website in the past week. It is looking to fill 37 spots at headquarters, another 32 at its commercial manufacturing plant in Morris Plains, NJ, and one person in Research Triangle Park, NC, where it has an important relationship with a supplier. Dendreon had just 198 total employees at last count on March 2, so this represents a 30 percent expansion.
The job descriptions posted online represent a broad range of skills Dendreon will need to maximize the value of sipuleucel-T (Provenge). Dendreon is looking for people in quality assurance and quality control, finance, marketing, human resources, and logistics. These people, together with the current Dendreon staff, will be charged with amending an application to the FDA to start marketing the drug in the U.S., and then producing enough of the drug to meet demand. Prostate cancer kills 30,000 men nationwide each year, and analysts predict the product—the first drug of its kind likely to win FDA approval—will go on to exceed $1 billion a year in sales.
Dendreon has been mum about the commercial game plan it needs to execute to make this really happen, deferring all questions about strategy to an analyst day it plans to host this summer. But it confirmed the massive push is on to hire and grow.
“Dendreon is beginning hiring to support the regulatory and commercial plans for Provenge,” said Katherine Stueland, a spokeswoman for the company....
6/5 2009 13:54 Hya 010156 New DeepCapture on NSS
With Media Absent, a Senator Reports the News
Posted on 05 May 2009 by Mark Mitchell
Last night, CNBC’s Jim Cramer interviewed Senator Ted Kaufman about the problem of abusive short selling.
The Senator said: “We gotta have people feel that they’re getting a fair share and the market’s on the level…Clearly, every indication is that things went on in terms of short selling – both in Bear Stearns and Lehman Brothers, but in others – where abusive short selling drove the price down and legitimate people in the market got mauled.”
That is to say: rampant naked short selling (hedge funds illegally selling phantom stock to destroy public companies for profit) helped trigger the greatest financial disaster since the Great Depression.
This is a scandal of some magnitude. That is why members of Congress on both sides of the aisle have demanded that the Securities and Exchange Commission take action. But aside from Cramer, the media remains silent. And the SEC is hopeless.
Today the SEC held a special meeting to discuss short selling, and it was a whitewash. The focus was on reinstating the uptick rule, which is precisely where the short sellers wanted the focus to be. No talk of taking the necessary steps to wipe out illegal naked short selling.
Instead, the SEC recommended “caution” in cracking down on the criminals and suggested that new short selling rules (enacted in the midst of last September’s meltdown) are “working.” The new rules are basically the same as the old rules. Whereas previously short sellers were required to deliver shares within three days, now short sellers are really required to deliver the stock within three days.
This new regime, like the old regime, has several shortcomings. The first is that hedge funds can continue to sell unlimited amounts of phantom shares within the three-day window. During these three days, the stock price naturally tanks, at which point the hedge funds buy the cheapened stock and cover their “short sales” (which are really fake long sales, for no stock was ever borrowed) at a profit. The hedge funds repeat this process over and over, every three days, until the stock is in the single digits and the company’s lenders panic, cutting off credit.
The second shortcoming of the new regime is that........
http://www.deepcapture.com/with-media-absent-a-senator-reports-the-news/
With Media Absent, a Senator Reports the News
Posted on 05 May 2009 by Mark Mitchell
Last night, CNBC’s Jim Cramer interviewed Senator Ted Kaufman about the problem of abusive short selling.
The Senator said: “We gotta have people feel that they’re getting a fair share and the market’s on the level…Clearly, every indication is that things went on in terms of short selling – both in Bear Stearns and Lehman Brothers, but in others – where abusive short selling drove the price down and legitimate people in the market got mauled.”
That is to say: rampant naked short selling (hedge funds illegally selling phantom stock to destroy public companies for profit) helped trigger the greatest financial disaster since the Great Depression.
This is a scandal of some magnitude. That is why members of Congress on both sides of the aisle have demanded that the Securities and Exchange Commission take action. But aside from Cramer, the media remains silent. And the SEC is hopeless.
Today the SEC held a special meeting to discuss short selling, and it was a whitewash. The focus was on reinstating the uptick rule, which is precisely where the short sellers wanted the focus to be. No talk of taking the necessary steps to wipe out illegal naked short selling.
Instead, the SEC recommended “caution” in cracking down on the criminals and suggested that new short selling rules (enacted in the midst of last September’s meltdown) are “working.” The new rules are basically the same as the old rules. Whereas previously short sellers were required to deliver shares within three days, now short sellers are really required to deliver the stock within three days.
This new regime, like the old regime, has several shortcomings. The first is that hedge funds can continue to sell unlimited amounts of phantom shares within the three-day window. During these three days, the stock price naturally tanks, at which point the hedge funds buy the cheapened stock and cover their “short sales” (which are really fake long sales, for no stock was ever borrowed) at a profit. The hedge funds repeat this process over and over, every three days, until the stock is in the single digits and the company’s lenders panic, cutting off credit.
The second shortcoming of the new regime is that........
http://www.deepcapture.com/with-media-absent-a-senator-reports-the-news/
6/5 2009 13:55 Hya 010157 Dendreon has 3 Conferences lined up for May...
Upcoming Events
May 12, 2009
9:20 AM ET Bank of America and Merrill Lynch 2009 Health Care Conference Listen to webcast
Remind me
Please sign up for email alert notification.
May 19, 2009
4:35 PM ET Deutsche Bank Securities 34th Annual Health Care Conference Listen to webcast
Remind me
Please sign up for email alert notification.
May 20, 2009
10:30 AM ET Leerink Swann Novel Cancer Thereapeutics: Oncology Roundtable Listen to webcast
Remind me
Upcoming Events
May 12, 2009
9:20 AM ET Bank of America and Merrill Lynch 2009 Health Care Conference Listen to webcast
Remind me
Please sign up for email alert notification.
May 19, 2009
4:35 PM ET Deutsche Bank Securities 34th Annual Health Care Conference Listen to webcast
Remind me
Please sign up for email alert notification.
May 20, 2009
10:30 AM ET Leerink Swann Novel Cancer Thereapeutics: Oncology Roundtable Listen to webcast
Remind me
6/5 2009 13:58 Hya 010158 Give it a rest
Jeez--all the squawking about options, dilution--Gold doesn't deserve it--why is the pps tanking, who is manipulating things, blah,blah,blah...
Dendreon has succeeded where dozens of other companies have failed. They have validated a technology platform to induce a patient's immune system to recognize cancerous cells as foreign and attack them. Never before in the long history of man and medicine has this been accomplished! Stop and think about that for a second.
And it is not just for one cancer--the technology--which is OWNED by Dendreon, PATENTED by Dendreon--is applicable to other cancers--look at the massive immune response already seen in the Neuvenge data--look at the clinical improvement in the women involved.
And the company accomplished this without having to partner with some heartless, monolithic, greedy Pharma. It owns ALL of it.
How much brighter could its future be??
Here's hoping for a poisonous pill to surpass all others so that the company can remain independent and truly meet its potential (rather than becoming a tiny, unappreciated, sliver of a "show me the money instantly or die" big pharma). Here's hoping for a ROW deal that keeps US rights to the pipeline with Dendreon while financing the pipeline's development with whopping payments and no capture of the company in the partnership. Here's hoping for shareholders and a BOD who have the patience and wisdom to see the company become the next Amgen, not the next Imclone or Icos.
But even if everyone fucks up and rushes to be taken over, the pps still doubles (instead of going to 1000)--so give it a rest. Watching the share price every second of every day and coming up with a new conspiracy theory every 5 minutes is a waste of everyone's time and Board space.
Anyone care to post on the topic of whether Dendreon will or should stay independent--and if it does whether it will become something extra fantastic and valuable??
I'm interested in intelligent analysis...
Jeez--all the squawking about options, dilution--Gold doesn't deserve it--why is the pps tanking, who is manipulating things, blah,blah,blah...
Dendreon has succeeded where dozens of other companies have failed. They have validated a technology platform to induce a patient's immune system to recognize cancerous cells as foreign and attack them. Never before in the long history of man and medicine has this been accomplished! Stop and think about that for a second.
And it is not just for one cancer--the technology--which is OWNED by Dendreon, PATENTED by Dendreon--is applicable to other cancers--look at the massive immune response already seen in the Neuvenge data--look at the clinical improvement in the women involved.
And the company accomplished this without having to partner with some heartless, monolithic, greedy Pharma. It owns ALL of it.
How much brighter could its future be??
Here's hoping for a poisonous pill to surpass all others so that the company can remain independent and truly meet its potential (rather than becoming a tiny, unappreciated, sliver of a "show me the money instantly or die" big pharma). Here's hoping for a ROW deal that keeps US rights to the pipeline with Dendreon while financing the pipeline's development with whopping payments and no capture of the company in the partnership. Here's hoping for shareholders and a BOD who have the patience and wisdom to see the company become the next Amgen, not the next Imclone or Icos.
But even if everyone fucks up and rushes to be taken over, the pps still doubles (instead of going to 1000)--so give it a rest. Watching the share price every second of every day and coming up with a new conspiracy theory every 5 minutes is a waste of everyone's time and Board space.
Anyone care to post on the topic of whether Dendreon will or should stay independent--and if it does whether it will become something extra fantastic and valuable??
I'm interested in intelligent analysis...
6/5 2009 15:58 Hya 010172 Dendreon Reports First Quarter 2009 Financial Results
SEATTLE, May 6, 2009 - Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008.
Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share compared to a net loss for the same quarter of 2008 of $19.5 million, or $0.23 per share. Cash, cash equivalents, short-term, and long-term investments at March 31, 2009 totaled $91.2 million compared to $108.5 million at December 31, 2008.
Recent Events:
Reported final analysis of the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) Phase 3 trial for PROVENGE (sipuleucel-T) which demonstrated a statistically significant increase in overall survival. Data were presented at the American Urological Association (AUA) Annual Meeting. Based on these data, the Company intends to amend its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.
Presented preclinical data at the AUA meeting announcing that D3263, a small molecule targeting TRPM8 (a transmembrane cation channel protein), reduced the size of the prostate in an animal model of benign prostatic hyperplasia (BPH) alone or in combination with finasteride.
Initiated a Phase 1 clinical trial of D3263 in patients with advanced cancer. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 targeting TRPM8 in patients with solid tumors that are refractory to standard therapies.
Presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APC), a measure of product potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
"The significant increase in overall survival demonstrated in our Phase 3 IMPACT trial for PROVENGE is a major milestone for the company and puts us one step closer to making PROVENGE available to patients with prostate cancer who currently have few appealing treatment options," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We look forward to reviewing our commercialization plans for PROVENGE in more detail during a webcast analyst day this summer."
In lieu of a conference call, the Company will present at several upcoming investor conferences that will be webcast, three of which are later this month and include:
Bank of America / Merrill Lynch 2009 Health Care Conference on May 12, 2009
Deutsche Bank 34th Annual Healthcare Conference on May 19, 2009
Leerink Swann Novel Cancer Therapeutics: Roundtable Conference on May 20, 2009
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
SEATTLE, May 6, 2009 - Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008.
Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share compared to a net loss for the same quarter of 2008 of $19.5 million, or $0.23 per share. Cash, cash equivalents, short-term, and long-term investments at March 31, 2009 totaled $91.2 million compared to $108.5 million at December 31, 2008.
Recent Events:
Reported final analysis of the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) Phase 3 trial for PROVENGE (sipuleucel-T) which demonstrated a statistically significant increase in overall survival. Data were presented at the American Urological Association (AUA) Annual Meeting. Based on these data, the Company intends to amend its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.
Presented preclinical data at the AUA meeting announcing that D3263, a small molecule targeting TRPM8 (a transmembrane cation channel protein), reduced the size of the prostate in an animal model of benign prostatic hyperplasia (BPH) alone or in combination with finasteride.
Initiated a Phase 1 clinical trial of D3263 in patients with advanced cancer. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 targeting TRPM8 in patients with solid tumors that are refractory to standard therapies.
Presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APC), a measure of product potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
"The significant increase in overall survival demonstrated in our Phase 3 IMPACT trial for PROVENGE is a major milestone for the company and puts us one step closer to making PROVENGE available to patients with prostate cancer who currently have few appealing treatment options," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We look forward to reviewing our commercialization plans for PROVENGE in more detail during a webcast analyst day this summer."
In lieu of a conference call, the Company will present at several upcoming investor conferences that will be webcast, three of which are later this month and include:
Bank of America / Merrill Lynch 2009 Health Care Conference on May 12, 2009
Deutsche Bank 34th Annual Healthcare Conference on May 19, 2009
Leerink Swann Novel Cancer Therapeutics: Roundtable Conference on May 20, 2009
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
6/5 2009 16:03 Hya 010173 RTTNews) - Wednesday, Dendreon Corp. (DNDN: News ) reported a first-quarter net loss of $15.4 million or $0.16 per share, compared to a loss of $19.5 million or $0.23 per share in the same quarter last year.
On average, six analysts polled by Thomson Reuters expected the company to report a loss of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.
Revenue for the quarter was $30.0 thousand, compared to $31.0 thousand in the comparable quarter last year. Analysts expected the company to report revenue of $110.0 thousand for the quarter.
On average, six analysts polled by Thomson Reuters expected the company to report a loss of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.
Revenue for the quarter was $30.0 thousand, compared to $31.0 thousand in the comparable quarter last year. Analysts expected the company to report revenue of $110.0 thousand for the quarter.
7/5 2009 13:09 Hya 010237 Dendreon Technical Analysis
For those interested in TA, I found these links on Dendreon worth a look.....
here's the stock TA site (note the bullish sentiment)....
http://www.stockta.com/cgi-bin/analysis.pl?symb=DNDN&num1=1&cobrand=&mode=stock
But the Point & Figure chart of Dendreon is truly amazing. Using the standard three box reversal, the bullish price objective is 60.75
http://stockcharts.com/def/servlet/SC.pnf?c=DNDN,P&listNum=
using a 4 box reversal, the price objective for DNDN is $80.
http://stockcharts.com/def/servlet/SC.pnf?chart=DNDN,PLTADANRBO[PA][D][F1!4!!!2!20]&pref=G
For those interested in TA, I found these links on Dendreon worth a look.....
here's the stock TA site (note the bullish sentiment)....
http://www.stockta.com/cgi-bin/analysis.pl?symb=DNDN&num1=1&cobrand=&mode=stock
But the Point & Figure chart of Dendreon is truly amazing. Using the standard three box reversal, the bullish price objective is 60.75
http://stockcharts.com/def/servlet/SC.pnf?c=DNDN,P&listNum=
using a 4 box reversal, the price objective for DNDN is $80.
http://stockcharts.com/def/servlet/SC.pnf?chart=DNDN,PLTADANRBO[PA][D][F1!4!!!2!20]&pref=G
8/5 2009 01:12 Hya 010362 Dendreon(DNDN Quote) is raising money.
The Seattle-based drug company is expected to sell 10 million shares in an overnight financing deal Thursday, according to a prospectus emailed to potential investors by Deutsche Bank Securities, which is handling the deal.
No firm information on pricing was provided, but multiple sources said the price range being considered is $18.70 to $19.20 a share, a slight discount to Dendreon's Thursday's closing price of $19.76. At the midpoint of the pricing range, gross proceeds would total $189.5 million.
Dendreon is also offering an over-allotment of 1.5 million shares, so the total money raised could be higher.
Dendreon's decision to raise money Thursday night comes a week after the company presented survival data for its prostate cancer vaccine Provenge at a medical meeting in Chicago.
og lidt om konsekvenser
$180 million in cash to the coffers of Dendreon? Whoa. That's huge. That will pay for the entire launch and then some. Wow. For only 10 million shares?
This is great news.... Schiffman has been on his toes.
Folks, this will be a great buying opportunity for it forces a higher multiple on anyone trying to grab Dendreon which is great news for all of us Longs. The traders will hate it in the short run. In the long run, we will be staying independent!!!
Also, this does reduce the need for a ROW for the cash in the near term. That can then be translated, a ROW will be for profiting existing shareholders.
Again, Great News for this investor.... if true.
The Seattle-based drug company is expected to sell 10 million shares in an overnight financing deal Thursday, according to a prospectus emailed to potential investors by Deutsche Bank Securities, which is handling the deal.
No firm information on pricing was provided, but multiple sources said the price range being considered is $18.70 to $19.20 a share, a slight discount to Dendreon's Thursday's closing price of $19.76. At the midpoint of the pricing range, gross proceeds would total $189.5 million.
Dendreon is also offering an over-allotment of 1.5 million shares, so the total money raised could be higher.
Dendreon's decision to raise money Thursday night comes a week after the company presented survival data for its prostate cancer vaccine Provenge at a medical meeting in Chicago.
og lidt om konsekvenser
$180 million in cash to the coffers of Dendreon? Whoa. That's huge. That will pay for the entire launch and then some. Wow. For only 10 million shares?
This is great news.... Schiffman has been on his toes.
Folks, this will be a great buying opportunity for it forces a higher multiple on anyone trying to grab Dendreon which is great news for all of us Longs. The traders will hate it in the short run. In the long run, we will be staying independent!!!
Also, this does reduce the need for a ROW for the cash in the near term. That can then be translated, a ROW will be for profiting existing shareholders.
Again, Great News for this investor.... if true.
8/5 2009 05:18 Hya 010403 Dendreon (DNDN) will sell 11.5 million shares in an overnight placement for about $19 a share, raising about $200 million. The company already has about 100 million shares outstanding, so this represents 11.5% dilution and brings my estimate of their current value down from $60 to $53. This is the last money DNDN should have to raise, ever. The stock dipped 5% today in advance of the placement. Normally, stocks move right back up after the deal is done, so I would not worry about it. DNDN remains a buy under $20 – hey, it’s there! - for my unchanged $40 target.
http://newworldinvestor.com/722/radar-report-5709/
http://newworldinvestor.com/722/radar-report-5709/
8/5 2009 23:30 Hya 010513 http://www.fda.gov/bbs/topics/NEWS/2009/NEW02014.html
og når vi så sammenligner med provenge til prostatacancer pt.er
så forlænger det livet med 4,5 mdr - mod avasin til hjernetumor i 4 mdr
men ser vi på bivirkningerne så har provenge stort set ingen - hvorimode de er meget alvorlige ved avasin
og i begge tilfælde taler vi om de allermest syge patienter hvor der ikke findes nogen behandling længere
Når jeg netop fremhæver denne godkendelse fra idag - er det for at lave et follow op på at jeg tror på at der er rigtig gode chancer for at provenge godkendes
der er 72 ledige stillinger på hjemmesiden idag
og der er gennemført salg af aktier så der er kapital nok til at fuldføre projektet frem til produktion efter godkendelse
og der har været insidersalg for denne omgang
og 3 konferencer i maj mdr der afventer
så nu er der kun "optionsudløb" der kan skubbe rundt med kursen
så jeg har øget min position i aften
forøvrigt flot af et biotek selskab at kunne rejse så meget kapital her under finanskrisen - der må være flere end mig der tror på casen.
Hya
Hya
og når vi så sammenligner med provenge til prostatacancer pt.er
så forlænger det livet med 4,5 mdr - mod avasin til hjernetumor i 4 mdr
men ser vi på bivirkningerne så har provenge stort set ingen - hvorimode de er meget alvorlige ved avasin
og i begge tilfælde taler vi om de allermest syge patienter hvor der ikke findes nogen behandling længere
Når jeg netop fremhæver denne godkendelse fra idag - er det for at lave et follow op på at jeg tror på at der er rigtig gode chancer for at provenge godkendes
der er 72 ledige stillinger på hjemmesiden idag
og der er gennemført salg af aktier så der er kapital nok til at fuldføre projektet frem til produktion efter godkendelse
og der har været insidersalg for denne omgang
og 3 konferencer i maj mdr der afventer
så nu er der kun "optionsudløb" der kan skubbe rundt med kursen
så jeg har øget min position i aften
forøvrigt flot af et biotek selskab at kunne rejse så meget kapital her under finanskrisen - der må være flere end mig der tror på casen.
Hya
Hya
10/5 2009 09:48 Hya 010640 DNDN research blog updated
New additions for today:
Casey's information on the reception the night before and the Annual Shareholder's meeting on June 10.
http://tinyurl.com/opvsos
Feuerstein on the DNDN secondary offering on May 7
http://tinyurl.com/o73aqq
Some IR answers on manufacturing/buildout from Jan (courtesy binarybit and strond)
http://tinyurl.com/pfap2j
Rufus on Dr. Gold and his motives
http://tinyurl.com/pbgulp
Article on Dr. Gold from 2004 by Timmerman
http://tinyurl.com/ovfz62
Rufus on why Provenge works when others have failed
http://tinyurl.com/qcel5z
http://dndninfo.blogspot.com/
New additions for today:
Casey's information on the reception the night before and the Annual Shareholder's meeting on June 10.
http://tinyurl.com/opvsos
Feuerstein on the DNDN secondary offering on May 7
http://tinyurl.com/o73aqq
Some IR answers on manufacturing/buildout from Jan (courtesy binarybit and strond)
http://tinyurl.com/pfap2j
Rufus on Dr. Gold and his motives
http://tinyurl.com/pbgulp
Article on Dr. Gold from 2004 by Timmerman
http://tinyurl.com/ovfz62
Rufus on why Provenge works when others have failed
http://tinyurl.com/qcel5z
http://dndninfo.blogspot.com/
11/5 2009 14:52 Hya 010740 Form 8-K for DENDREON CORP
--------------------------------------------------------------------------------
11-May-2009
Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On May 7, 2009, Dendreon Corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Deutsche Bank Securities Inc. (the "Underwriter"), relating to the public offering, issuance and sale of 10,700,000 shares of the Company's common stock. Pursuant to the Underwriting Agreement, the Underwriter has agreed to purchase, subject to customary closing conditions, such shares of common stock from the Company at a price of $18.45 per share, which will result in $197.4 million in net proceeds to the Company before deducting offering expenses. The shares of common stock will be listed on the Nasdaq Global Market. The sale of the shares of the Company's common stock is expected to close on May 13, 2009. The Company has also granted the Underwriter a 30-day option to purchase up to 1,279,166 additional shares of common stock on the same terms and conditions as set forth above, to cover over-allotments. On May 8, 2009, the Underwriter provided notice to the Company that it intends to exercise such option in full.
The offering is being made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-151573) (the "Registration Statement"), as amended, including the related prospectus dated August 29, 2008 and the prospectus supplement dated May 7, 2009, each on file with the Securities and Exchange Commission.
A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and incorporated herein by reference. The Company's press release announcing the offering is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
1.1 Underwriting Agreement, dated as of May 7, 2009, between the Company and Deutsche Bank Securities Inc.
99.1 Dendreon Corporation press release, dated May 8, 2009.
--------------------------------------------------------------------------------
11-May-2009
Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On May 7, 2009, Dendreon Corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Deutsche Bank Securities Inc. (the "Underwriter"), relating to the public offering, issuance and sale of 10,700,000 shares of the Company's common stock. Pursuant to the Underwriting Agreement, the Underwriter has agreed to purchase, subject to customary closing conditions, such shares of common stock from the Company at a price of $18.45 per share, which will result in $197.4 million in net proceeds to the Company before deducting offering expenses. The shares of common stock will be listed on the Nasdaq Global Market. The sale of the shares of the Company's common stock is expected to close on May 13, 2009. The Company has also granted the Underwriter a 30-day option to purchase up to 1,279,166 additional shares of common stock on the same terms and conditions as set forth above, to cover over-allotments. On May 8, 2009, the Underwriter provided notice to the Company that it intends to exercise such option in full.
The offering is being made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-151573) (the "Registration Statement"), as amended, including the related prospectus dated August 29, 2008 and the prospectus supplement dated May 7, 2009, each on file with the Securities and Exchange Commission.
A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and incorporated herein by reference. The Company's press release announcing the offering is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
1.1 Underwriting Agreement, dated as of May 7, 2009, between the Company and Deutsche Bank Securities Inc.
99.1 Dendreon Corporation press release, dated May 8, 2009.
11/5 2009 14:59 Hya 010742 denne og ovenstående meddelse omhandler det samme -
MEN sjovt at se forskellen i den måde det formidles på
hvor den øverste virker negativ KUN 18,45
og den nederste positiv 19,2
hvor beløbet de fik ud af det er ens!
Hya
Issue PRICE, from Dendreon e-mail just now
We are offering 10,700,000 shares of our common stock.
Our common stock is quoted on the NASDAQ Global Market under the symbol “DNDN.” On May 7,
2009, the closing price of our common stock on the NASDAQ Global Market was $19.76 per share.
Investing in our common stock involves significant risks. See “Risk Factors”
on page S-6 of this prospectus supplement and Item 1A, “Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2008.
Neither the Securities and Exchange Commission, or SEC, nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
We have granted the underwriter the option to purchase from us up to 1,279,166 additional shares of
common stock on the same terms and conditions as set forth above if the underwriter sells more
than 10,700,000 shares in this offering. The underwriter can exercise this option at any time, in
whole or in part, within 30 days after the offering.
The underwriter expects to deliver the shares against payment on or about May 13, 2009.
Deutsche Bank Securities
May 7, 2009.
Per Share Total
Public offering price $ 19.20 $ 205,440,000
Underwriting discounts and commissions $ 0.75 $ 8,025,000
Proceeds to us, before expenses $ 18.45 $ 197,415,000
MEN sjovt at se forskellen i den måde det formidles på
hvor den øverste virker negativ KUN 18,45
og den nederste positiv 19,2
hvor beløbet de fik ud af det er ens!
Hya
Issue PRICE, from Dendreon e-mail just now
We are offering 10,700,000 shares of our common stock.
Our common stock is quoted on the NASDAQ Global Market under the symbol “DNDN.” On May 7,
2009, the closing price of our common stock on the NASDAQ Global Market was $19.76 per share.
Investing in our common stock involves significant risks. See “Risk Factors”
on page S-6 of this prospectus supplement and Item 1A, “Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2008.
Neither the Securities and Exchange Commission, or SEC, nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
We have granted the underwriter the option to purchase from us up to 1,279,166 additional shares of
common stock on the same terms and conditions as set forth above if the underwriter sells more
than 10,700,000 shares in this offering. The underwriter can exercise this option at any time, in
whole or in part, within 30 days after the offering.
The underwriter expects to deliver the shares against payment on or about May 13, 2009.
Deutsche Bank Securities
May 7, 2009.
Per Share Total
Public offering price $ 19.20 $ 205,440,000
Underwriting discounts and commissions $ 0.75 $ 8,025,000
Proceeds to us, before expenses $ 18.45 $ 197,415,000
11/5 2009 18:17 Hya 010783 Dendreon Corp. $ 19.24
DNDN -0.52
Short Interest (Shares Short) 21,611,400
Days To Cover (Short Interest Ratio) 1.3
Short Percent of Float 23.06 %
Short Interest - Prior 19,374,900
Short % Increase / Decrease 11.54 %
Short Squeeze Ranking™ 67
% From 52-Wk High ($ 22.10 ) -14.86 %
% From 52-Wk Low ($ 2.55 ) 86.75 %
% From 200-Day MA ($ 4.54 ) 76.40 %
% From 50-Day MA ($ 4.49 ) 76.66 %
Price % Change (52-Week) 222.40 %
Shares Float 93,720,000
Total Shares Outstanding 100,852,438
% Owned by Insiders 7.61 %
% Owned by Institutions 44.00 %
Market Cap. $ 1,940,400,907
Trading Volume - Today 8,213,106
Trading Volume - Average 16,375,400
Trading Volume - Today vs. Average 50.16 %
Earnings Per Share -0.79
PE Ratio
Record Date 2009-AprilB
Sector Healthcare
Industry Biotechnology
Exchange NAS
Da
DNDN -0.52
Short Interest (Shares Short) 21,611,400
Days To Cover (Short Interest Ratio) 1.3
Short Percent of Float 23.06 %
Short Interest - Prior 19,374,900
Short % Increase / Decrease 11.54 %
Short Squeeze Ranking™ 67
% From 52-Wk High ($ 22.10 ) -14.86 %
% From 52-Wk Low ($ 2.55 ) 86.75 %
% From 200-Day MA ($ 4.54 ) 76.40 %
% From 50-Day MA ($ 4.49 ) 76.66 %
Price % Change (52-Week) 222.40 %
Shares Float 93,720,000
Total Shares Outstanding 100,852,438
% Owned by Insiders 7.61 %
% Owned by Institutions 44.00 %
Market Cap. $ 1,940,400,907
Trading Volume - Today 8,213,106
Trading Volume - Average 16,375,400
Trading Volume - Today vs. Average 50.16 %
Earnings Per Share -0.79
PE Ratio
Record Date 2009-AprilB
Sector Healthcare
Industry Biotechnology
Exchange NAS
Da
12/5 2009 01:11 Hya 010823 hvor vi kan se et massivt fald i shortpositioner
04/30/2009 12,483,400 (42.24) 17,621,424 1.00
04/15/2009 21,611,442 11.54 16,375,362 1.32
der er fortsat optionsudløb d 15
og konference imorgen
May 12, 2009
9:20 AM ET Bank of America and Merrill Lynch 2009 Health Care Conference
som kan høres via deres hjemmeside.
Hya
04/30/2009 12,483,400 (42.24) 17,621,424 1.00
04/15/2009 21,611,442 11.54 16,375,362 1.32
der er fortsat optionsudløb d 15
og konference imorgen
May 12, 2009
9:20 AM ET Bank of America and Merrill Lynch 2009 Health Care Conference
som kan høres via deres hjemmeside.
Hya
15/5 2009 20:40 stengård 011229 der var i går en heftig spekulation i at dr var en monsterportion optioner der skulle dækkes ind... hmmmm - foreløbigt ligger det da stille ?
Kan man have "rullet" dem ?
Kan man have "rullet" dem ?
